On Friday, Aquestive Therapeutics Inc (NASDAQ: AQST) was unchanged from the session before settling in for the closing price of $2.38. A 52-week range for AQST has been $2.12 – $5.80.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
Over the past five-year period, the growth rate of yearbook sales for the company of the Healthcare sector was 2.34%. When this article was written, the company’s average yearly earnings per share was at -35.73%. With a float of $87.10 million, this company’s outstanding shares have now reached $99.32 million.
Considering the fact that the conglomerate employs 142 people, you should pay attention to its efficiency factor. In terms of profitability, gross margin is 59.06%, operating margin of -75.94%, and the pretax margin is -100.05%.
Aquestive Therapeutics Inc (AQST) Insider Activity
Also, it is sometimes useful to examine the sentiment of large-scale investors toward Aquestive Therapeutics Inc stocks. The insider ownership of Aquestive Therapeutics Inc is 12.31%, while institutional ownership is 42.69%. The most recent insider transaction that took place on Nov 26 ’24, was worth 214. In this transaction Chief Operating Officer of this company sold 44 shares at a rate of $4.87, taking the stock ownership to the 0 shares.
Aquestive Therapeutics Inc (AQST) Earnings and Forecasts
According to the Wall Street analysts, stocks earnings will be around -35.73% per share during the next fiscal year. For the long-term projections, market analysts anticipate that the company’s EPS will surge by 14.57% during the next five years compared to 27.90% growth over the previous five years of trading.
Aquestive Therapeutics Inc (NASDAQ: AQST) Trading Performance Indicators
You can see what Aquestive Therapeutics Inc (AQST) is doing with its current performance indicators. In the most recent quarter, the stock posted a quick ratio of 4.48. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 4.36.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -0.58, a number that is poised to hit -0.17 in the next quarter and is forecasted to reach -0.59 in one year’s time.
Technical Analysis of Aquestive Therapeutics Inc (AQST)
Compared to the last year’s volume of 1.62 million, its volume of 3.8 million showed improvement in the last five days. As of the previous 9 days, the stock’s Stochastic %D was 24.49%. Additionally, its Average True Range was 0.22.
During the past 100 days, Aquestive Therapeutics Inc’s (AQST) raw stochastic average was set at 15.57%, which indicates a significant decrease from 27.99% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 103.65% in the past 14 days, which was higher than the 73.71% volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $2.77, while its 200-day Moving Average is $3.76. Nevertheless, the first resistance level for the watch stands at $2.46 in the near term. At $2.54, the stock is likely to face the second major resistance level. The third major resistance level sits at $2.60. If the price goes on to break the first support level at $2.32, it is likely to go to the next support level at $2.26. Should the price break the second support level, the third support level stands at $2.18.
Aquestive Therapeutics Inc (NASDAQ: AQST) Key Stats
There are 99,328K outstanding shares of the company, which has a market capitalization of 236.40 million. As of now, sales total 57,560 K while income totals -44,140 K. Its latest quarter income was 11,870 K while its last quarter net income were -17,060 K.
